5月8日晚间，再鼎医药（ZLAB）股价夜盘大涨5.18%，主要受到公司发布的2025年第一季度财报超预期影响。
根据财报，再鼎医药2025年第一季度总收入达到1.065亿美元，同比增长22%。其中，产品收入净额为1.057亿美元，较去年同期的8710万美元增长21%。值得注意的是，公司经营亏损显著改善，第一季度为5630万美元，同比下降20%；调整后的经营亏损减少25%至3710万美元，显示公司正稳步迈向盈利目标。
再鼎医药重申了全年收入指引为5.6亿至5.9亿美元，并表示公司正朝着2025年第四季度实现盈利的目标迈进。此外，公司在产品研发方面也取得积极进展，包括多个候选药物的临床试验进展。这些因素共同推动了投资者对再鼎医药未来发展前景的信心，促使股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.